Original Study| Volume 15, ISSUE 6, P696-703, December 2017

Management of Renal Masses in an Octogenarian Cohort: Is There a Right Approach?



      We reviewed the outcomes for an octogenarian population to investigate whether active surveillance (AS) provides comparable survival to partial nephrectomy (PN) or radical nephrectomy (RN).

      Patients and Methods

      Data were collected from 115 octogenarian patients referred for management of renal masses at Moffitt Cancer Center from 2000 to 2013. Patients were treated with AS, PN, or RN. Univariable and multivariable Cox regression models measured the association between management modality and survival. Kaplan-Meier survival analysis was used to calculate survival, and log-rank tests were used to compare survival curves.


      The median age was 82 years (interquartile range, 81-85 years). The median follow-up period was 51 months (interquartile range, 23-81 months). Of the 115 patients, 31 (27%) underwent AS, 31 (27%) underwent PN, and 53 (46%) underwent RN. The patients who underwent RN had a larger mean tumor size at 5.5 cm, with 19 patients (36%) having stage ≥ pT3 (P < .001). We found no difference in overall survival or disease-specific survival among the 3 management strategies on univariable analysis (P = .39 and P = .1, respectively). On multivariable analysis for overall survival, only the Charlson comorbidity index was associated with worse survival (hazard ratio, 1.2; 95% confidence interval, 1.1-1.3; P = .002). In a subgroup analysis of cT1a patients, we also found no difference in overall or disease-specific survival among the treatment arms on univariable analysis (P = .74 and P = .9, respectively).


      Active treatment with PN and RN might not provide a survival advantage compared with AS in the octogenarian population with a small renal mass. However, larger renal masses should undergo active treatment in appropriately selected patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2016.
        CA Cancer J. 2016; 66: 7-30
        • Chow W.H.
        • Devesa S.S.
        • Warren J.L.
        • Fraumeni Jr., J.F.
        Rising incidence of renal cell cancer in the United States.
        JAMA. 1999; 281: 1628-1631
        • Motzer R.J.
        • Jonasch E.
        • Agarwal N.
        • et al.
        Kidney cancer, version 3.2015.
        J Natl Compr Canc Netw. 2015; 13: 151-159
        • Volpe A.
        • Panzarella T.
        • Rendon R.A.
        • Haider M.A.
        • Kondylis F.I.
        • Jewett M.A.
        The natural history of incidentally detected small renal masses.
        Cancer. 2004; 100: 738-745
        • Patel N.
        • Cranston D.
        • Akhtar M.Z.
        • et al.
        Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy.
        BJU Int. 2012; 110: 1270-1275
        • Rais-Bahrami S.
        • Guzzo T.J.
        • Jarrett T.W.
        • Kavoussi L.R.
        • Allaf M.E.
        Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention.
        BJU Int. 2009; 103: 1355-1358
        • Huang W.C.
        • Atoria C.L.
        • Bjurlin M.
        • et al.
        Management of small kidney cancers in the new millennium: contemporary trends and outcomes in a population-based cohort.
        JAMA Surg. 2015; 150: 664-672
        • Kim S.P.
        • Gross C.P.
        • Meropol N.
        • et al.
        National treatment trends among older patients with T1-localized renal cell carcinoma.
        Urol Oncol. 2016; 35: 113.e15-113.e21
        • Arias E.
        United States life tables, 2010.
        Natl Vital Stat Rep. 2014; 63: 1-63
        • Tomaszewski J.J.
        • Uzzo R.G.
        • Kutikov A.
        • et al.
        Assessing the burden of complications after surgery for clinically localized kidney cancer by age and comorbidity status.
        Urology. 2014; 83: 843-849
        • Lane B.R.
        • Abouassaly R.
        • Gao T.
        • et al.
        Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older.
        Cancer. 2010; 116: 3119-3126
      1. Celtik KE, Shah PH, Patel VR, et al. Active surveillance for incidental renal mass in the octogenarian [e-pub ahead of print]. World J Urol., accessed November 1, 2016.

        • Russell D.H.
        • Wachtel M.S.
        • de Riese H.W.
        • Haynes A.L.
        • de Riese W.T.
        Implications on clinical management of the small renal mass in patients 80 years of age and older based on a retrospective review of the SEER database.
        Int Urol Nephrol. 2015; 47: 1503-1508
        • O'Connor K.M.
        • Davis N.
        • Lennon G.M.
        • Quinlan D.M.
        • Mulvin D.W.
        Can we avoid surgery in elderly patients with renal masses by using the Charlson comorbidity index?.
        BJU Int. 2009; 103: 1492-1495
        • Abouassaly R.
        • Lane B.R.
        • Novick A.C.
        Active surveillance of renal masses in elderly patients.
        J Urol. 2008; 180: 505-509
        • Chawla S.N.
        • Crispen P.L.
        • Hanlon A.L.
        • Greenberg R.E.
        • Chen D.Y.
        • Uzzo R.G.
        The natural history of observed enhancing renal masses: meta-analysis and review of the world literature.
        J Urol. 2006; 175: 425-431
        • Clark P.E.
        • Spiess P.E.
        • Agarwal N.
        • et al.
        Penile cancer: Clinical practice guidelines in oncology.
        J Natl Compr Canc Netw. 2013; 11: 594-615
        • Hakenberg O.W.
        • Comperat E.M.
        • Minhas S.
        • et al.
        EAU guidelines on penile cancer: 2014 update.
        Eur Urol. 2015; 67: 142-150
        • Pierorazio P.M.
        • Johnson M.H.
        • Ball M.W.
        • et al.
        Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry.
        Eur Urol. 2015; 68: 408-415
        • Wehle M.J.
        • Thiel D.D.
        • Petrou S.P.
        • Young P.R.
        • Frank I.
        • Karsteadt N.
        Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy.
        Urology. 2004; 64: 49-52
        • Smaldone M.C.
        • Kutikov A.
        • Egleston B.L.
        • et al.
        Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis.
        Cancer. 2012; 118: 997-1006
        • Zini L.
        • Perrotte P.
        • Jeldres C.
        • et al.
        A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses.
        BJU Int. 2009; 103: 899-904
        • Patel H.D.
        • Kates M.
        • Pierorazio P.M.
        • et al.
        Survival after diagnosis of localized T1a kidney cancer: current population-based practice of surgery and nonsurgical management.
        Urology. 2014; 83: 126-132
        • Go A.S.
        • Chertow G.M.
        • Fan D.
        • McCulloch C.E.
        • Hsu C.Y.
        Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
        N Engl J Med. 2004; 351: 1296-1305